CoQ10 and D-ribose in Patients With Diastolic Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.
Also called NCT03133793
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 216 participants
- Registry
-
NCT03133793
-
- Other papers using this trial's data
- Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03133793. Randomized; double masking; primary purpose treatment. Start 2018-02-05 (actual); primary completion 2021-03-12 (actual). Results posted on 2022-03-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CoQ10 and D-ribose in Patients With Diastolic Heart Failure
- Condition
- Heart Failure, Diastolic
- Intervention (Drug)
- CoQ10
- Intervention (Drug)
- D-Ribose Oral Powder
- Intervention (Other)
- Placebo pills
- Intervention (Other)
- Placebo powder
- Lead sponsor
- University of Kansas Medical Center
- Collaborator
- National Institute on Aging (NIA)
Record details
- Record id
cardio:ct-nct03133793- Content hash
d51b0de19a924722dcea81949a3e52e81033c5ac7621eaa25dff369387a09a10